Stable renal engraftment in a patient following successful tandem autologous/reduced-intensity conditioning allogeneic transplantation for treatment of multiple myeloma with del(17p) that developed as a post-transplantation lymphoproliferative disease following renal transplantation

Autologous Bone Marrow-Derived Mesenchymal Stromal Cells for the Treatment of Allograft Rejection After Renal Transplantation: Results of a Phase I Study

(2013) Marlies E.J. Reinders et al.   Stem Cells Translational Medicine

Impact of High-Risk Cytogenetics and Achievement of Molecular Remission on Long-Term Freedom from Disease after Autologous–Allogeneic Tandem Transplantation in Patients with Multiple Myeloma

(2012) Nicolaus Kröger et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Improving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-risk multiple myeloma

(2012) P. L. Bergsagel et al.   BLOOD

Donor versus no-donor comparison of newly diagnosed myeloma patients included in the HOVON-50 multiple myeloma study

(2012) H. M. Lokhorst et al.   BLOOD

Bortezomib-Based Graft-Versus-Host Disease Prophylaxis in HLA-Mismatched Unrelated Donor Transplantation

(2012) John Koreth et al.   JOURNAL OF CLINICAL ONCOLOGY

ABO-incompatible kidney transplantation

(2012) Kota Takahashi et al.   Transplantation Reviews

Related transplantation with HLA-1 Ag mismatch in the GVH direction and HLA-8/8 allele-matched unrelated transplantation: a nationwide retrospective study

(2011) J. Kanda et al.   BLOOD

Lenalidomide maintenance after nonmyeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 Trial

(2011) E. Kneppers et al.   BLOOD

Impact of genetic abnormalities after allogeneic stem cell transplantation in multiple myeloma: a report of the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire

(2011) D. Roos-Weil et al.   HAEMATOLOGICA

Tandem Autologous/Reduced-Intensity Conditioning Allogeneic Stem-Cell Transplantation Versus Autologous Transplantation in Myeloma: Long-Term Follow-Up

(2011) Bo Björkstrand et al.   JOURNAL OF CLINICAL ONCOLOGY

Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial

(2011) Amrita Krishnan et al.   LANCET ONCOLOGY

Impact of Human Leukocyte Antigen-DR Mismatch Status on Kidney Graft Survival in a Predominantly African-American Population Under the Newer Immunosuppressive Era

(2011) I. Karabicak et al.   TRANSPLANTATION PROCEEDINGS

Bortezomib Plus Dexamethasone Induction Improves Outcome of Patients With t(4;14) Myeloma but Not Outcome of Patients With del(17p)

(2010) Hervé Avet-Loiseau et al.   JOURNAL OF CLINICAL ONCOLOGY

Cost of Paid Transplantation Abroad: Possible Donor-Origin Early Multiple Myeloma in a Renal Transplant Recipient Treated Using Bortezomib

(2010) Y. Solak et al.   TRANSPLANTATION PROCEEDINGS

A Phase II Trial of Autologous Stem Cell Transplantation Followed by Mini-Allogeneic Stem Cell Transplantation for the Treatment of Multiple Myeloma: An Analysis of Eastern Cooperative Oncology Group ECOG E4A98 and E1A97

(2009) David H. Vesole et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13

(2009) D. Reece et al.   BLOOD

Nonmyeloablative allografting for newly diagnosed multiple myeloma: the experience of the Gruppo Italiano Trapianti di Midollo

(2008) B. Bruno et al.   BLOOD